Who We Are
We are a global coalition of investigators united in a common mission to develop new treatments for X-Linked Dystonia-Parkinsonism (XDP), a rare neurodegenerative disease affecting individuals from the island of Panay in the Philippines. Our structure is organized around core faculty labs at Massachusetts General Hospital (MGH) that are connected to a network of basic scientists, clinical investigators, and patient advocates at institutions throughout North America, Europe, and Asia. Working together as a consortium, our scientists have identified the pathogenic gene variant associated with XDP and are developing new stem cell and animal models for probing disease mechanisms and testing candidate therapeutics. Now with an expanding consortium of academic investigators and industry partners, we are moving faster than ever before to translate our basic discoveries into potential new therapies.